Related Experiment Video

Updated: Jun 21, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

[The role of EGFR in non-small cell lung carcinoma]

S Peters1, D C Betticher

  • 1Centre pluridisciplinaire d'oncologie, CHUV, 1011 Lausanne.

Revue Medicale Suisse
|July 8, 2009
PubMed

Insights

Epidermal Growth Factor Receptor (EGFR) targeted therapies show promise for metastatic non-small cell lung carcinoma (NSCLC). Research is ongoing to identify predictive factors for optimizing patient selection for treatments like cetuximab and erlotinib.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Epidermal Growth Factor Receptor (EGFR) is frequently expressed in non-small cell lung carcinoma (NSCLC).
  • The role of EGFR in NSCLC oncogenesis and progression varies significantly among patients.
  • Targeted therapies against EGFR are crucial in managing metastatic NSCLC.

Purpose of the Study:

  • To review current EGFR-targeting agents for metastatic NSCLC.
  • To discuss the efficacy and application of cetuximab and erlotinib.
  • To highlight the importance of identifying predictive factors for treatment selection.

Main Methods:

  • Literature review of EGFR-targeted therapies in NSCLC.
  • Analysis of clinical data for cetuximab and erlotinib.
  • Discussion of ongoing research in predictive biomarker identification.

Main Results:

  • Cetuximab, an EGFR antibody, offers moderate survival benefit with chemotherapy in first-line treatment.
  • Erlotinib, an EGFR tyrosine-kinase inhibitor, is utilized in later treatment lines (2nd/3rd).
  • Identifying predictive factors is critical for patient stratification.

Conclusions:

  • EGFR-targeted therapies represent a significant advancement in metastatic NSCLC treatment.
  • Personalized treatment strategies incorporating predictive biomarkers are essential for maximizing therapeutic benefits.
  • Further research is needed to refine patient selection for EGFR-targeted agents.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...